201 related articles for article (PubMed ID: 17335312)
1. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
Lieberman JA
J Clin Psychiatry; 2007 Feb; 68(2):e04. PubMed ID: 17335312
[TBL] [Abstract][Full Text] [Related]
2. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
3. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
Nasrallah HA
J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
Foussias G; Remington G
Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
Rosenheck RA; Lieberman JA
J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
7. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotics and metabolics in the post-CATIE era.
Meyer JM
Curr Top Behav Neurosci; 2010; 4():23-42. PubMed ID: 21312396
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of atypical antipsychotic medications versus conventional medication.
Hanrahan P; Luchins DJ; Fabian R; Tolley G
Expert Opin Pharmacother; 2006 Sep; 7(13):1749-58. PubMed ID: 16925502
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
14. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
Glazer WM; Conley RR; Citrome L
CNS Spectr; 2006 Sep; 11(9 Suppl 10):1-13; quiz 14. PubMed ID: 16946697
[TBL] [Abstract][Full Text] [Related]
15. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
Rosenheck RA; Leslie DL; Doshi JA
Psychiatr Serv; 2008 May; 59(5):515-20. PubMed ID: 18451007
[TBL] [Abstract][Full Text] [Related]
16. Understanding the results of CATIE in the context of the field.
Glick ID
CNS Spectr; 2006 Jul; 11(7 Suppl 7):40-7. PubMed ID: 16816799
[TBL] [Abstract][Full Text] [Related]
17. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP
J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332
[TBL] [Abstract][Full Text] [Related]
18. Lessons to take home from CATIE.
Carpenter WT; Buchanan RW
Psychiatr Serv; 2008 May; 59(5):523-5. PubMed ID: 18451009
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
Attard A; Taylor DM
CNS Drugs; 2012 Jun; 26(6):491-508. PubMed ID: 22668246
[TBL] [Abstract][Full Text] [Related]
20. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
